Back to Results

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Study category: Bones, Muscles, and Joints

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Must be 18-75 years of age History of Psoriatic Arthritis of 6 months or more Have active Psoriatic Arthritis with 3 or more swollen joints and 3 or more tender joints Have a Serum CRP equal or greater than 6

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Christopher Striebich

Christopher Striebich

Study ID

Protocol Number: 19-2533

More information available at ClinicalTrials.gov: NCT04115748

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers